These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21208841)

  • 1. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
    Berg M; Soreide K
    Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
    Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
    J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
    Hendifar A; Tan CR; Annamalai A; Tuli R
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
    Okada Y; Miyamoto H; Goji T; Takayama T
    Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biomarker for chemotherapy in patients with colorectal cancer].
    Matsusaka S
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):11-4. PubMed ID: 19151559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
    Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
    Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
    Osera S; Yoshino T
    Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work.
    Stintzing S; Stremitzer S; Sebio A; Lenz HJ
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):43-60. PubMed ID: 25475572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
    Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
    Heinemann V; Douillard JY; Ducreux M; Peeters M
    Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice.
    Maurel J; Postigo A
    Curr Cancer Drug Targets; 2015; 15(8):703-15. PubMed ID: 26452385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting.
    Rolfo C; Russo A; Santini D; Bronte G; Peeters M
    Expert Opin Ther Targets; 2013 Aug; 17(8):869-71. PubMed ID: 23848525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.